We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Alterity Therapeutics Limited | NASDAQ:ATHE | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0012 | 0.06% | 1.9612 | 1.92 | 2.02 | 2.018 | 1.95 | 1.95 | 3,809 | 21:00:01 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2024
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
99.1 | Notice Under Section 708A |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Alterity Therapeutics Limited | ||
By: | /s/ Geoffrey P. Kempler | |
Geoffrey P. Kempler | ||
Chairman |
Date: January 8, 2024
2
Exhibit 99.1
ASX ANNOUNCEMENT | 8 January 2024 |
Notice Under Section 708A(5)(e) of the Corporations Act
This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).
Details of securities issued
Type | Shares | |
Class/Description | Fully paid ordinary shares | |
ASX Code | ATH | |
Date of Issue | 8 January 2024 | |
Number Issued | 1,008,965,805 |
The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:
1. | the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; |
2. | as at the date of this notice, the Company has complied with: |
(i) | the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and |
(ii) | sections 674 and 674A of the Corporations Act; and |
3. | as at the date of this notice there is no information to be disclosed which is ‘excluded information’ (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company. |
Phillip Hains
Company Secretary
Alterity Therapeutics Limited ACN 080 699 065
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com
1 Year Alterity Therapeutics Chart |
1 Month Alterity Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions